ALECTOR INC (ALEC)
US0144421072 - Common Stock
Commit To Purchase Alector At $2.50, Earn 8.2% Annualized Using Options
Investors Land ALEC 26.7% Cheaper Than Its Secondary Stock Offering
Commit To Purchase Alector At $5, Earn 29% Annualized Using Options
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.
Notable Two Hundred Day Moving Average Cross - ALEC
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting Wednesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on this morning!
Alector to Participate in Upcoming Healthcare Conferences
Alector to Participate in Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering...
Alector GAAP EPS of -$0.49 beats by $0.28, revenue of $15.2M beats by $6.36M (NASDAQ:ALEC)
Alector's Q4 earnings beat expectations with a higher revenue, and the company provides guidance for collaboration and expenses in 2024.
Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer’s disease (AD), expected in Q4 2024; trial...
Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call
Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PT
Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call
Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. ...
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease
The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globally
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease
The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globally...
Alector stock gain on FDA breakthrough tag for dementia drug
GSK (GSK) and Alector (ALEC) receive FDA breakthrough therapy designation for latozinemab, a potential treatment for rare form of dementia. Read more here.
FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
-Latozinemab is the most advanced progranulin-elevating candidate in development for FTD-GRN and has now become the first investigational medicine to...
Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
These three companies are developing treatments for brain diseases that have a great deal of potential, making them top neuroscience stocks.
Investors Land ALEC 17.0% Cheaper Than Its Secondary Stock Offering
Alector Announces Closing of Public Offering
Alector Announces Closing of Public Offering
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering...
ALEC Makes Notable Cross Below Critical Moving Average
Alector down 16%, prices $75M worth equity offering (NASDAQ:ALEC)
Alector, a biotech company, prices underwritten public offering of shares, raising $75M. Offering set to close on January 19, 2024.
Alector Announces Pricing of Public Offering of Common Stock
Alector Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering...
Alector intends to conduct a public offering of its shares (NASDAQ:ALEC)
Alector plans to offer and sell shares of its common stock in an underwritten public offering, with an option for additional purchases.
Alector Announces Proposed Public Offering of Common Stock
Alector Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering...
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Stifel upgrades Alector to buy, stock rallies 18% (NASDAQ:ALEC)
Alector (ALEC) shares rallied 18% after Stifel upgraded the stock to a buy, citing the company's Alzheimer's drug candidate AL002. Read more here.